Navigation Links
Framingham Study Shows Parents Who Live Long Pass On Lower Risk of,Cardiovascular Disease

BETHESDA, Md., March 13, 2007--New evidence suggests that if you could choose your parents, you could reduce your risk of cardiovascular disease. Researchers from the long-standing Framingham Heart Study (FHS), a program of the National Heart, Lung, and Blood Institute (NHLBI) of the National Institutes of Health, report that people whose parents live longer were more likely to avoid developing high blood pressure, high cholesterol, and other risk factors for cardiovascular disease in middle age than their peers whose parents died younger. They also found that the risk factor advantages persisted over time.

According to the researchers, this is the first study to examine cardiovascular risk factors in the offspring of longer-lived individuals using independent and validated measurements of risk. The findings are consistent with other studies that have linked lower cardiovascular risk with parental longevity based on self-reports of family history.

"Characteristics of Framingham Offspring Participants with Long-Lived Parents, appears in the March 12 issue of the Archives of Internal Medicine.

In the study, researchers examined 1,697 offspring age 30 and older (average age 40) whose parents participated in the original FHS and had reached age 85 or died before January 1, 2005. They compared cardiovascular risk factors among the offspring based on whether both parents, one parent, or neither parent lived to 85 years or older. The risk factors included age, sex, education, cigarette smoking, blood pressure, cholesterol, and body mass index (BMI). In addition, they compared the offsprings' Framingham Risk Scores, a summary score based on the combined contribution of traditional cardiovascular risk factors.

In general, the group in which both parents survived to age 85 had significantly fewer participants with high blood pressure or who were current smokers, compared to those in which both parents or one parent had died. In addition, the middle-aged children of long-lived parents had significantly lower levels of blood pressure and blood cholesterol, and they had lower Framingham Risk Scores than those in which one or both parents had died. Overall, parental longevity did not significantly affect BMI. After 12 years of follow up, the offspring of longer-lived parents were also less likely to progress to high blood pressure and to generate higher risk scores, the researchers report.

NHLBI's Framingham Heart Study has studied the health of many of the Massachusetts towns residents since 1948. The community-based research program has been the source of key research findings regarding the contributions of hypertension, high cholesterol, cigarette smoking, and other risk factors to the development of cardiovascular disease. Now assessing a third generation of participants, Framingham Heart Study investigators are expanding their research into other areas such as the role of genetic factors in cardiovascular disease as well as the use of novel biomarkers and new diagnostic tests to identify individuals at high risk.

Daniel Levy, M.D., Director of the Framingham Heart Study, and other FHS investigators are available to comment on the study's findings as well as how modifiable risk factors can lower cardiovascular disease risk.

To schedule interviews, contact the NHLBI Communications Office at 301-496-4236.

RESOURCES:

Part of the National Institutes of Health, the National Heart, Lung, and Blood Institute (NH LBI) plans, conducts, and supports research related to the causes, prevention, diagnosis, and treatment of heart, blood vessel, lung, and blood diseases; and sleep disorders. The Institute also administers national health education campaigns on women and heart disease, healthy weight for children, and other topics. NHLBI press releases and other materials are available online at www.nhlbi.nih.gov.

The National Institutes of Health (NIH) — The Nation's Medical Research Agency — includes 27 Institutes and Centers and is a component of the U.S. Department of Health and Human Services. It is the primary federal agency for conducting and supporting basic, clinical and translational medical research, and it investigates the causes, treatments, and cures for both common and rare diseases. For more information about NIH and its programs, visit www.nih.gov.


CONTACT:
NHLBI Communications Office
301-496-4236
'"/>




Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
3. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
4. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
5. Reaction to Avandia Warnings Stronger Among Internists Than Endocrinologists, According to Study by GfK Market Measures
6. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
8. Protox Announces Positive Clinical Data from Prostate Cancer Study
9. International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE prophylaxis
10. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
11. Genzyme Announces Data from First Phase 3 Study of Tolevamer in Patients with C. difficile Associated Diarrhea
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/10/2016)... 2016 CERS ), Medivation, Inc. (NASDAQ: ... and Celldex Therapeutics, Inc. (NASDAQ: CLDX ). --> ... Pharmaceuticals, Inc. (NASDAQ: ADMS ) and Celldex Therapeutics, Inc. ... Drug Designations become vitally important in the development of targeted ... and biologics which are defined as those intended for the ...
(Date:2/10/2016)... 2016 ALSP, Inc. announced that it has appointed ... Medical Affairs in preparation for its move into clinical trials ... CEO, stated, "We are pleased to welcome Dallas Hack ... with an individual of such practical knowledge and far-reaching experience ... deeply on his broad experience and success as a clinician ...
(Date:2/10/2016)... 9, 2016 On Tuesday, February ... met with its Arthritis Advisory Committee to ... Johnson & Johnson,s Remicade and most likely ... the U.S. The Biologics Prescribers Collaborative (BPC) ... Alliance for Patient Access, American Association of ...
Breaking Medicine Technology:
(Date:2/10/2016)... (PRWEB) , ... February 10, 2016 , ... ... working together to expand dental health services to the developmentally disabled in the ... Care Dental’s operations to a new facility at 71-949 Highway 111, Suite 100-B, ...
(Date:2/10/2016)... (PRWEB) , ... February 10, 2016 , ... ... tracking solution, The Guard, to associations of medical professionals throughout the country. The ... including security risk assessments, policies and procedures, employee training, regulatory updates, and compliance ...
(Date:2/10/2016)... ... ... Dr. Jessica Barron, of Barron Family Dental in Thornton, Colorado , is ... the North Metro Denver area. The new dental practice focuses on comfort where patients ... the most relaxing environment. , While some dental visits can create anxiety for patients, ...
(Date:2/10/2016)... ... ... AxoGen, Inc. (NASDAQ: AXGN), a leading medical technology company focused on the peripheral ... December 31, 2015 on Monday, February 29, 2016 after the market closes. , The ... release at 4:30 PM ET. Investors interested in participating by phone are invited to ...
(Date:2/10/2016)... MN (PRWEB) , ... February 10, 2016 , ... ... that it will attend the Ohio Safety Congress and Expo event March 9-11, ... at the Greater Columbus Convention Center. , As the longest running and ...
Breaking Medicine News(10 mins):